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The amyloid-42 (A42) peptide has been suggested to
play a causative role in Alzheimer disease (AD). Neprilysin
(NEP) is one of the rate-limiting A-degrading enzymes, and
its enhancement ameliorates extracellular amyloid pathol-
ogy, synaptic dysfunction, and memory defects in mouse
models of A amyloidosis. In addition to the extracellular
A, intraneuronal A42 may contribute to AD pathogenesis.
However, the protective effects of neuronal NEP expression
on intraneuronal A42 accumulation and neurodegenera-
tion remain elusive. In contrast, sustained NEP activation
may be detrimental because NEP can degrade many physio-
logical peptides, but its consequences in the brain are not
fully understood. Using transgenic Drosophila expressing
human NEP and A42, we demonstrated that NEP efficiently
suppressed the formation of intraneuronal A42 deposits
and A42-induced neuron loss. However, neuronal NEP
overexpression reduced cAMP-responsive element-binding
protein-mediated transcription, caused age-dependent axon
degeneration, and shortened the life span of the flies. Inter-
estingly, the mRNA levels of endogenous fly NEP genes and
phosphoramidon-sensitive NEP activity declined during
aging in fly brains, as observed in mammals. Taken together,
these data suggest both the protective and detrimental effects
of chronically high NEP activity in the brain. Down-regula-
tion of NEP activity in aging brains may be an evolutionarily
conserved phenomenon, which could predispose humans to
developing late-onset AD.
Alzheimer disease (AD)3 is a progressive neurodegenerative
disease defined by two protein deposits in autopsied brains:
extracellular amyloid plaques composed of the 40- or 42-amino
acid-amyloid peptides (A40 orA42), and intracellular neu-
rofibrillary tangles composed of abnormally hyperphosphoryl-
ated microtubule-associated protein Tau (1). A peptides are
physiological metabolites of the amyloid precursor protein
(APP) resulting from sequential cleavage by -secretase and
-secretase complex, whose catalytic subunits are presenilin 1
(PS1) and presenilin 2 (PS2) (2). Molecular genetic studies of
early onset familial AD patients have identified causativemuta-
tions inAPP, PS1, and PS2 genes, and thesemutations promote
A42 production, aggregation, and stability against clearance
(3). Thus, the increased A42 levels in the brain are believed to
initiate AD pathogenesis.
The mechanisms by which A42 reaches pathological lev-
els in the brains of late-onset AD (LOAD) patients are not
well understood. The steady state level of A42 in the brain
reflects the balance between production and clearance, and a
reduction in clearance activity would raise A42 levels. A
deficiency in neprilysin (NEP), a major rate-limiting A-de-
grading enzyme (4, 5), accelerates formation of extracellular
amyloid deposits (6), amyloid angiopathy (6), synaptic dys-
functions (7), and memory defects (7) caused by human A
in transgenic mice. In LOAD patients, NEP mRNA and pro-
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tein levels are selectively reduced in brain regions highly
vulnerable to AD pathology (8), and NEP levels and activity
decrease in human and rodent brains with aging (9–12), sug-
gesting that reduction in NEP levels may contribute to the
onset and/or progression of LOAD.
Activation of NEP could be a potential disease-modifying
therapy for AD. Transgenic (13, 14), viral (15, 16), or ex vivo
delivery (17) of NEP to brains of APP transgenic mice reduces
extracellular amyloid deposits, synaptic dysfunction, and pre-
mature death. Intraneuronal accumulations of A42 have also
been detected in AD brains (18, 19) and may contribute to AD
pathogenesis. Intraneuronal A is highly toxic in cultured neu-
rons (20, 21), and transgenic Drosophila expressing human
A42 peptides in the secretory pathway of neurons exhibited
age-dependent behavioral defects and neurodegeneration with
intraneuronal A42 accumulation (22, 23). Some transgenic
mice overproducing A accumulate A intraneuronally, prior
to extracellular amyloid pathologies (24–26). These intraneu-
ronalA accumulationswere correlatedwith synaptic dysfunc-
tion (25), memory defects (27, 28), and neurodegeneration
(29–31). However, little is known about the effects of NEP on
intraneuronal A42 accumulation and toxicity.
In contrast to the potential benefits of enhanced A clear-
ance, sustained NEP activation may be detrimental (32),
because NEP can degrade a wide range of circulating peptides,
including enkephalin, atrial natriuretic peptide, endothelin,
and substance P (33). Although transgenic mice expressing
high levels of human NEP do not show detectable adverse
effects (13), potential side effects of a chronic increase in NEP
activity have not been fully established.
In this study, we demonstrated that expression of human
NEP in transgenic A42 fly brains effectively reduced A42
levels, intraneuronal A42 deposits, and neuron loss. However,
chronic NEP activity attenuated CREB-mediated transcription
measured by an in vivoCRE-luciferase reporter, caused age-de-
pendent axon degeneration, and shortened the life span of the
flies. Interestingly, mRNA levels and activity of endogenous fly
NEPs in brains reduced with aging as observed in humans.
EXPERIMENTAL PROCEDURES
Establishment of Transgenic Fly Lines, Genetics, and Culture
Conditions—The cDNA constructs for human NEP and an
inactive mutant NEP were obtained from Drs. T. Saido and K.
Shirotani (RIKEN, Japan). These cDNAs were cloned into the
pUAST Drosophila transformation vector and microinjected
into fly embryos of the w1118 (isoCJ1) genotype. Several trans-
genic lines for each NEP construct were established. Trans-
genic A42 flies were established as described (22, 23). The
transgenicUAS-CD8::GFP;;OK107 line was a kind gift fromDr.
L. Luo. The elav-GAL4c155 flies were obtained from the Bloom-
ington Drosophila Stock Center (Indiana University). When
flies were raised at 25 °C throughout development, the expres-
sion of NEP, but not NEPmut, caused infertile phenotypes,
including wet body and folded wing, presumably because of its
ability to degrade circulating endogenous fly peptides (data not
shown). Thus, flies were placed at 18 °C during development to
reduce the activity of Gal4 and transgene (NEP and A42)
expression, and were maintained at 25 °C, under conditions of
70% humidity and a 12:12-h light:dark cycle after eclosion. This
treatment dramatically prevented developmental defects
induced by NEP, but it was sufficient to induce A42-induced
behavioral defects and neurodegeneration in adult flies. The
transgenic UAS-dCREB2b (dnCREB) and CRE-luciferase
reporter (CRE-Luc) lines were described previously (34).
Because the expression of dnCREB caused infertile phenotypes
when raised at 25 °C (data not shown), flies were placed at 18 °C
during development and were maintained at 27 °C, under con-
ditions of 70% humidity and a 12:12-h light:dark cycle after
eclosion.
Western Blotting—To examine the expression levels of NEP,
NEPmut, and dCREB2 proteins, heads from flies at 1–2 days-
after-eclosion (dae) were homogenized in Tris-glycine sample
buffer (Invitrogen) and centrifuged at 13,000 rpm for 10 min,
and the supernatants were separated on 10% Tris-glycine gels
(Invitrogen) and transferred to nitrocellulose membranes
(Invitrogen). The membranes were blocked with 5% nonfat dry
milk (Nestle´) and blotted with the anti-NEP antibody (Novo-
castra) or anti-dCREB2 antibody (a kind gift from Dr. J. Yin).
For sequential extractions of A42, fly heads were homoge-
nized in RIPA buffer (50 mM Tris-HCl, pH 8.0, 0.5% sodium
deoxycholate, 1% Triton X-100, 150 mM NaCl) containing 1%
SDS. Lysates were centrifuged at 100,000 g for 1 h, and super-
natants were collected (SDS-soluble fraction). SDS-insoluble
pellets were further homogenized in 70% formic acid (Sigma)
followed by centrifugation at 13,000 rpm for 20 min, and the
supernatants were collected (formic acid fraction). Formic acid
was evaporated by SpeedVac (Savant, SC100), and protein was
resuspended in dimethyl sulfoxide (Sigma). Protein extracts
were separated on 10–20% Tris-Tricine gels (Invitrogen) and
transferred to nitrocellulosemembranes. Themembraneswere
boiled in phosphate-buffered saline (PBS) for 3 min, blocked
with 5% nonfat dry milk, and blotted with the 6E10 antibody
(Signet).
Neprilysin Enzymatic Assay—Around 30 fly heads from the
appropriate genotype and age were homogenized in 25 mM
Tris-HCl, pH 7.4, and centrifuged at 1,000 rpm for 5 min. The
enzymatic activity of the supernatant was assayed using glu-
taryl-Ala-Ala-Phe-4-methoxy-2-naphthylamide (Sigma) as a
substrate in the presence or absence of phosphoramidon
(Sigma), as described previously (35). Recombinant human
neprilysin was purchased from R & D Systems. Protein levels
were quantified using Micro BCA protein assay kit (Pierce).
Whole-mount Immunostaining and Thioflavine S Staining—
Transgenic fly brains expressing NEP or NEPmut in the mush-
room body structure were dissected in cold PBS, fixed in PBS
containing 4% paraformaldehyde (Electron Microscopy Sci-
ences), and then placed under vacuum in PBS containing 4%
paraformaldehyde and 0.25% Triton X-100. After permeabili-
zation with PBS containing 2% Triton X-100, the brains were
boiled in citrate buffer (Chemicon) for 5min and stained with a
mouse monoclonal anti-NEP antibody (Novocastra) followed
by detection with biotin-XX goat anti-mouse IgG and strepta-
vidin-Texas Red conjugate (Molecular Probes). The dendritic
and axonal structures of the mushroom body neurons were
visualized with the co-expressed CD8-GFP signal. The brains
were analyzed using a confocal microscope (Carl Zeiss LSM
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510). For thioflavin S (TS) staining, the brains were permeabi-
lized and incubated in 50% EtOH containing 0.1% TS (Sigma)
overnight. After washing in 50%EtOHandPBS, the brainswere
analyzed using a confocalmicroscope. The numbers of TS-pos-
itive deposits were quantified from six hemispheres from three
flies per genotype. The fluorescence intensity in Kenyon cell
regions in the same images was measured using NIH image.
Quantification of Neurodegeneration—Heads were fixed in
4% paraformaldehyde, processed to embed in paraffin blocks,
and sectioned at a thickness of 6 m. Sections were placed on
slides, stained with hematoxylin and eosin (Vector Laborato-
ries), and examined by bright field microscopy. To quantify
neurodegeneration in the cell body and neuropil, images of the
sections were captured, and the areas of the vacuoles in the cell
body or neuropil regions were measured using Photoshop
(Adobe Systems). The ratio of lost area in the cell body region
was calculated by dividing the sum of the vacuole areas by the
total area of the cell body region.
Survival Assay—Food vials containing 25 flies were placed on
their sides at 25 °C, under conditions of 70% humidity and a
12:12-h light:dark cycle. Food vials were changed every 2–3
days, and the number of dead flies was counted each time. At
least four vials for each genotype were prepared. Experiments
were repeated more than three times, and a representative
result was shown.
Transmission Electron Microscopy—Probosces were re-
moved from decapitated heads, which were then immersion-
fixed overnight in 4% glutaraldehyde and 2% paraformaldehyde
in 0.1 M PBS. Samples were post-fixed 1 h in ferrocyanide-re-
duced osmium tetroxide (1% osmium tetroxide and 1.5% potas-
sium ferrocyanide). Fixation was followed by dehydration in a
graded alcohol series and infiltration with LR White resin (2 h
in 50% LRWhite in ethanol and 24 h in 100% LRWhite) using
constant rotation. After transferring the samples to gelatin cap-
sules with fresh LRWhite resin, the samples were polymerized
overnight at 60 °C. Thin sections (100 nm) of neuropil regions
were collected on nickel grids (100 mesh, Veco-EMS). Grids
were then rinsed in 10 drops of distilled water and air-dried.
Thin sections were stained for 5 min in 3% uranyl acetate dis-
solved in 30% ethanol and then rinsed in distilled water.
Luciferase Assay—In vivo luciferase activity was recorded
from flies as described (34). Briefly, CRE-Luc flies were loaded
in 96-well plates filled with agar containing sucrose and lucife-
rin (Biosynth) and covered with PCR caps and clear plastic cov-
ers (Topseal, PerkinElmer Life Sciences) that had holes
punched in them. Activity was measured by using a Topcount
microplate scintillation and luminescence counter (Perkin-
Elmer Life Sciences) under a 12:12-h light:dark cycle. Experi-
ments were repeatedmore than three times, and the represent-
ative data are shown.
Quantitative Real Time PCR Analysis—For each sample,
200–300 flies were collected and frozen at 2, 10, and 25 dae.
Headsweremechanically isolated, and total RNAwas extracted
using TRIzol (Invitrogen) according to themanufacturer’s pro-
tocol with an additional centrifugation step (11,000  g for 10
min) to remove cuticle membranes prior to the addition of
chloroform. Total RNA was reverse-transcribed using Super-
script II reverse transcriptase (Invitrogen), and the resulting
cDNA was used as a template for PCR on a 7500 fast real time
PCR system (Applied Biosystems). The average threshold cycle
value (Ct) was calculated from five replicates per sample.
Expression of NEP1–5 was standardized relative to TBP. Rela-
tive expression values were determined by the Ct method
according the formula 2(Ct), whereCt is the difference in
Ct at different time points (where d is day) (Ctx,2d-
Ctx,10d, or Ctx,2d-Ctx,25d), and Ctx is the difference in
threshold cycles for target (Ct NEP1–5) and reference (CtTBP)
according to quantitative PCR Analysis User Bulletin (Applied
Biosystems). To confirm the specificity of the PCR, PCR prod-
ucts were electrophoresed on agarose gels. Primers were
designed using PrimerExpress 3.0 (Applied Biosystems) to
detect NEP1–5 and TBP as follows: NEP1, GATGACGCAGG-
GCGAGAA (forward) and TGGGCGTAGTTGAGAAAG-
AACA (reverse); NEP2, CCGCAGATGGGCTGAGAA (for-
ward) and TGCACGCCGGTAGTAATACG (reverse); NEP3,
GTCCAGCCGCACCAAAAA (forward) and CCATTGATT-
GCAGGAATATCCA (reverse); NEP4, ACGCTCTCGAACT-
CCGTTGA (forward) and AGGAATGTGTGGCATATGT-
CATG (reverse); NEP5, GCACCCACCTGGAGAACCT
(forward) and GGCACAGTGATTGCATTCGA (reverse); and
TBP, GCGGCTGTGATTATGCGAAT (forward) and AGGG-
AAACCGAGCTTTTGGA (reverse).
RESULTS
Establishment of Human NEP and Mutant NEP (NEPmut)
Transgenic Flies—To determine the effects of neuronal expres-
sion of human NEP on intraneuronally expressed A42-in-
duced pathology and toxicity in the brain, we established trans-
genic flies expressing human NEP utilizing the Gal4-UAS
system (36). We also created transgenic lines carrying an inac-
tive mutant form of human NEP (NEPmut) with an amino acid
substitution of Glu at 585 to Val in the zinc-binding motif of
neprilysin, as controls (37, 38). The NEP or NEPmut proteins
were expressed in all fly neurons under the control of the pan-
neuronal elav-Gal4 driver, and expression levels in fly heads
were determined byWestern blotting (Fig. 1A). The flies carry-
ing elav-Gal4 driver alone were used as a control. In this study,
we used primarily the NEP3 and NEP45 lines for wild-type
human NEP and the NEPmut18 and NEPmut30 lines for inac-
tive mutant NEP, because the levels of expression were compa-
rable. To achieve higher levels of expression of NEP and NEP-
mut in flies, we prepared double transgenic flies carrying NEP3
and NEP45 (NEP345) or NEP18 and NEP30 (NEP-
mut1830). Head lysates from NEP flies (NEP45 and
NEP345) showed 3-fold more catalytic activity toward the
fluorogenic NEP substrate, glutaryl-Ala-Ala-Phe-4-methyoxy-
2-naphthylamide, compared with control flies (Fig. 1B). In con-
trast, lysates from NEPmut fly brains (NEPmut1830) show
basal NEP activity comparable with that in control flies (Fig.
1B). These results demonstrate that human NEP protein
expressed in the fly brain forms an active enzyme.
Preferential Localization of NEP and NEPmut Proteins in
Axons and Dendrites—NEP proteins are detected in axons and
dendrites inmammalian neurons (39, 40). To examine the neu-
ronal distribution patterns of human NEP and NEPmut pro-
teins, we used theOK107-gal4 driver to specifically express the
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proteins in the mushroom body structure, in which the cell
bodies (Kenyon cell bodies), dendrites (calyxes), and axons
(lobes) of Kenyon cells are readily identifiable (41) (Fig. 2).
Mushroom bodies are paired structures formed from 2,500
cells in each hemisphere, which play a central role in olfactory
learning and memory in flies. The mushroom body calyxes,
located just beneath the mushroom body cell bodies (Kenyon
cell bodies) in the dorsal posterior brain, delineate the dendritic
fields of the intrinsic mushroom body neurons. The axons of
mushroom body neurons (lobes) extend anteriorly and branch
into the dorsally projecting lobes (42).
Whole-mount immunostaining with an anti-NEP antibody
strongly detected NEP and NEPmut proteins in the axons and
dendrites (Fig. 2), indicating that human NEP proteins
expressed in fly neurons exhibit a cellular localization similar to
that in mammalian neurons. These results suggest that the cel-
lularmechanism that localizes NEP proteins to neuritesmay be
conserved between fly and human.
Reduced Brain A42 Levels and TS-positive Deposits by NEP,
but not NEPmut, Expression—To determine whether overex-
pression of human NEP can reduce the intraneuronal accumu-
lation of A42, we expressed NEP or NEPmut in transgenic
A42 fly brains. In thismodel, A42 peptideswere expressed in
the endoplasmic reticulum (ER), and they were detected in the
Golgi apparatus, lysosomes, dendrites, axons, and presynaptic
terminals by immunoelectron microscopy (immuno-EM) (23).
In fly brains,monomericA42 peptideswere detected as 4-kDa
signals in both detergent-soluble (extractedwith RIPA contain-
ing 1% SDS) and detergent-insoluble fractions (extracted with
70% formic acid) by Western blotting (22). Expression of NEP,
but notNEPmut, significantly reduced the level of A42 both in
detergent-soluble and -insoluble fractions in aged A42 brains.
However, quantification of A42 signals showed that there
was a significant level of residual A42 in both fractions even
in flies carrying two copies of the NEP transgene (Fig. 3).
NEP did not change the level of a co-expressed CD8::GFP
fusion protein (Fig. 2), confirming the specificity of NEP
activity on A42 levels.
We tested whether neuronal expression of NEP can prevent
formation of intraneuronal TS-positive A42 deposits in the
cell body regions. Quantification of whole mount TS staining
revealed that TS-positive A42 deposits were dramatically
reduced by NEP, but not NEPmut, expression (Fig. 4, A–E).
These results demonstrate that neu-
ronal overexpression of NEP signif-
icantly reduced accumulation and
deposition of intraneuronally ex-
pressed A42 in the fly brain. Simi-
lar results were obtained in another
independent A42 transgenic line
(data not shown).
Suppression of A42-induced
Neuron Loss by NEP, but not NEP-
mut, Expression—Expression of
A42, but not A40, caused age-de-
pendent neuron loss, which could
be identified by the appearance of
vacuoles in the cell body regions of
fly brains (22). We examined the
effect of neuronal expression of
NEP on this phenotype (Fig. 5,
A–D). Quantification of the area
covered by vacuoles revealed that
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FIGURE 1. Characterization of expression levels and activity of human
NEP and NEPmut in fly brains. A, expression levels of NEP or NEPmut in
independent transgenic lines were compared by Western blotting. Equal
amounts of proteins were loaded. B, NEP, but not NEPmut, expressed in fly
brains exhibited phosphoramidon-sensitive endopeptidase activity. Arbi-
trary fluorescence units for each sample were compared with a standard
curve prepared using recombinant human neprilysin (rhNEP) to determine
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human NEP/mg fly head protein in control, NEP45, NEP345, and NEP-
mut1830, respectively.Bars indicate averagesS.E. (n3or 4). Theasterisk
indicates significant difference from control (p 5 109, Student’s t test).
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FIGURE 2. Axonal and dendritic localization of NEP and NEPmut in fly brain neurons. NEP or NEPmut
proteinswere expressed inmushroombody structures,where Kenyon cell body regions, axonbundles (Lobes),
anddendrites (Calyxes) canbeeasily identified, using theOK107-Gal4driver. Lobes andcalyxeswere labeledby
co-expressed membrane targeting mCD8::GFP fusion proteins (green). Immunostaining with an anti-human
NEP antibody (Anti-NEP, magenta) reveals preferential localization of NEP or NEPmut in axons (lobes) and
dendrites (calyxes) (Merge, white). Control brains without NEP transgene do not show any signal from human
NEP antibody, indicating the specificity of antibody. The cell body region is outlined in yellow. A schematic of a
sagittal view of mushroom body structure is shown at the top.
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NEP, but not NEPmut, dramatically suppressed neuron loss
(Fig. 5E), suggesting that the NEP-sensitive A42 population
contributes to neuron loss inA42 fly brains. The rescue effects
of NEP were confirmed in another independent A42 trans-
genic line (data not shown).
No Rescue of A42-induced Premature Death by NEP
Expression—Expression of A42 in neurons causes premature
death of flies (22). We found that neuronal NEP expression did
not rescue this phenotype (average life spans, 42, 38, 37, 40,
and 41 dae for A42, A42NEP3, A42NEP45,
A42NEP345, and A42NEPmut1830 flies, respec-
tively) (Fig. 6), whereas neuron loss was greatly suppressed in
NEP flies (Fig. 5). These results suggest that the residual frac-
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positive deposits (left panel) and signal intensity (right panel) in a hemisphere
are presented as averages S.D. (n 6 hemispheres). Asterisks indicate sig-
nificant differences from A42NEP345 (p 0.05, Student’s t test).
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cell body regions are shown as averages S.D. (n 7–9 hemispheres). Aster-
isks indicate significant differences fromA42 alone (p 0.00005, Student’s t
test).
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tion of A42may play a role in premature death in our A42 fly
models (Fig. 3). Additionally, the detrimental effects of NEP
expression may contribute to this phenotype (see below). Sim-
ilar results were obtained in another independent A42 trans-
genic line (data not shown).
Shortened Life Span of Flies with Neuronal NEP
Overexpression—NEP is capable of degrading many physiolog-
ical peptides (33), and sustained activation of NEP in neurons
may have detrimental effects. We found that neuronal expres-
sion of NEP significantly shortened the life span of flies relative
to controls (average life spans, 65, 52, 52, 48, 68, and 63 dae for
control, NEP45, NEP47, NEP345, NEPmut18, and NEP-
mut1830 flies, respectively, Fig. 7). Importantly, the expres-
sion ofNEPmut did not show this detrimental effect, suggesting
that not merely protein overexpression but NEP activity is
responsible for this premature death phenotype. AlthoughNEP
transgenic flies (average life spans, 52, 52, and 48 dae forNEP45,
NEP47, and NEP345, respectively) lived significantly longer
than A42 flies (average life span, 42 dae), the detrimental
effect of NEP may partly explain why NEP expression failed to
rescue A42-induced premature death.
Age-dependent Neuropil Degeneration and Axon Pathology
Induced by NEP Expression—To gain more insight into the
potential detrimental effects of neuronal NEP overexpression,
we examined the brains of aged (56 dae) NEP flies.We detected
neurodegeneration in the neuropil regions, including superior
lateral protocerebrum, as indicated by the many vacuoles in
NEP fly brains (Fig. 8A, arrowheads in pink region), compared
with NEPmut and control brains (Fig. 8, C andD, respectively).
This degeneration is age-dependent, because no vacuole was
observed in young (8 dae) fly brains overexpressing NEP (Fig.
8B). Quantification of the area covered by vacuoles is shown in
Fig. 8E. The degeneration was limited to neuropil regions, and
no significant cell body loss was observed in NEP flies (Fig. 8A,
no vacuoles in the cell body region (purple area)), which is
consistent with the preferential distribution of NEP in axons
and dendrites (Fig. 2). Moreover, despite a broad expression of
NEP in fly brain neurons by the pan-neuronal elav-Gal4 driver,
the degenerationwas observed in specific neuropil regions such
as superior lateral protocerebrum, suggesting that certain types
of neurons aremore vulnerable to excessiveNEP activity. At the
ultrastructural level, highly swollen axons were observed in
NEP fly brains (Fig. 8, F and G, asterisks) but not in control
brains (Fig. 8, H and I, arrows indicate normal axons). Taken
together, our results demonstrate that chronic NEP expression
in fly brains causes age-dependent axon pathology in certain
types of neurons.
Reduction in CREB-mediated Transcription Induced by Neu-
ronal NEP Overexpression—What is a potential mechanism(s)
underlying the observed detrimental effects of NEP? Because
NEP can degrade many physiological peptides, its artificial
overexpression would disrupt diverse signaling pathways acti-
vated byNEP-sensitive peptides in fly brains. Several neuropep-
tides are known to stimulate G-protein-coupling receptors and
activate CRE-binding protein family transcription factor,
which is an evolutionary conserved key mediator of stimulus-
induced transcription of pro-survival factors (43). We hypoth-
esized that NEP overexpression may reduce CREB-mediated
transcription in flies. CREB activity can be measured using
transgenic flies carrying the luciferase reporter gene fused to a
promoter region containing the CRE sequence (34). As
described previously, CREB activity oscillates in a circadian-de-
pendentmanner (Fig. 9, control) (34). In flies expressingNEP in
neurons, CREB activity was lower than that in control flies at all
time points, whereas a reduction in CREB activity was not
observed in flieswithNEPmut expression (Fig. 9). Neurodegen-
eration was not observed in flies with NEP overexpression at
this age (3–8 dae, Fig. 8).
Premature Death Induced by a Reduction in CREBActivity in
Neurons—To test the hypothesis that detrimental effects of
NEP expression is, in part, attributable to reduced CREB activ-
ity in neurons, we analyzed the effect of neuronal overexpres-
sion of the dCREB2-b repressor isoform (dnCREB) (44, 45). The
dnCREB proteins were expressed in all fly neurons under the
control of the pan-neuronal elav-Gal4 driver (Fig. 10A). As
expected, dnCREB expression in neurons reduced CREB activ-
ity in flies (Fig. 10B). We found that neuronal expression of
dnCREB significantly shortened the life span of flies (average
life span, 36 dae) relative to controls (average life span, 48 dae)
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(Fig. 10C). Similar results were obtained from several inde-
pendent transgenic lines for dnCREB (data not shown). In con-
trast, neurodegeneration was not prominent in dnCREB fly
brains (data not shown), suggesting that NEP-induced neuro-
degeneration is conferred by other mechanism(s). Taken
together, these results indicate that premature death induced
by chronic NEP expression may be explained by a reduction in
CREB activity in neurons.
Age-dependent Reduction in mRNA Levels of NEP Family
Genes and Phosphoramidon-sensitive NEP Activity in Fly
Brains—Although the underlying biological mechanisms are
not well understood, age-dependent reductions in NEPmRNA
levels have been reported in human and rodent brains (9–12,
46, 47). We were motivated to test whether a similar phenom-
enon can be seen in the fly brain. In theDrosophila genome, five
NEP family genes (NEP1–5) have been identified. NEP1 and
NEP3 are the fly homologues of human NEP and endothelin-
converting enzyme 1 (ECE1), rate-limiting A-degrading
enzymes in the mouse brain, respectively. We compared the
expression level of NEP genes in fly heads at 2, 10, and 25 dae by
quantitative reverse transcription-PCR. ThemRNA levels of all
NEPs, with the exception of NEP2, showed an age-dependent
decrease (NEP1, -3, and -5 showed approximate 40% reduc-
tions and NEP4 showed an approximate 20% reduction at 25
dae; Fig. 11, A, C, D, and E). We also detected that phosphor-
amidon-sensitive NEP activity in 26 dae (old) fly heads showed
a 40% reduction compared with that in 2 dae (young) (Fig. 11F).
These results suggest that down-regulation of NEP transcrip-
tion and activity with aging in brains may be an evolutionarily
conserved phenomenon across animal phyla.
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DISCUSSION
Emerging evidence suggests that intraneuronal accumula-
tion of A42may be an early event in AD pathogenesis and can
be an important therapeutic target (48). In this study, we dem-
onstrated that neuronal expression of human NEP reduced
intraneuronal accumulation of A42 and suppressed A42-in-
duced neuron loss in transgenic Drosophila brains. However,
our results also showed that chronic neuronal expression of
NEP reduced CREB-mediated transcription, caused age-
dependent axon degeneration, and shortened the life span of
the flies.
Mechanisms underlying A42 accumulation within neurons
are not well understood. In AD patients or transgenic AD
model mice brains, A has been detected in several organelles,
including the ER (49), Golgi apparatus (49), endosomal-lysoso-
mal system (50), as well as multivesicular bodies (51), autoph-
agolysosomes (52), mitochondria (53), and nuclei (21). Under
normal conditions, the endosome system is a major cellular
compartment for A generation (54). However, evidence sug-
gests that A can be generated intracellularly from the secre-
tory pathway (55). For example, A42, but not A40, can be
produced in the ER (56–59). In addition, A secreted into the
extracellular space can be taken up by neurons and internalized
into intracellular pools (60). Thus, under abnormal conditions,
A might be generated, retained, or recycled back to several
intracellular locations, thus facilitating the pathological intran-
euronal accumulation (61).
NEP is a type 2 membrane protein identified as a major rate-
limiting A-degrading enzyme in the brain (4, 5). NEP is a
member of the neutral endopeptidase family, which exhibits
maximum catalytic activity in neutral pH environments (33).
Thus, NEP would appear to degrade Amost efficiently in the
extracellular space. However, recent reports have shown that
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not only extracellular but also intraneuronal A levels are
reduced by NEP overexpression in primary cortical neurons,
presumably by degradation in the secretory pathway (62).
Moreover, a potential intracellular role for NEP in A catabo-
lism in vivo has recently been suggested from analysis of the
half-life of interstitial fluid A in NEP knock-out mice (6).
In our transgenic A42 flies, A42 peptides were expressed
in the ER and localized to the late secretory pathway compart-
ments, axons, dendrites, and presynaptic termini, as well as
secreted fromneurons (23). Here, we demonstrated that, in this
flymodel, neuronal overexpression of humanNEP significantly
reduced brain A42 levels and intraneuronal TS-positive
deposits (Fig. 3) and also significantly suppressed A42-in-
duced neuron loss (Fig. 4). Our results suggest that up-regula-
tion of neuronal NEP activity is protective against intraneuro-
nal A42 accumulation and neuron loss induced by
intracellularly generated A42.
Despite high expression levels of NEP, a significant amount
of A42 was still detected by Western blotting in A42 fly
brains (Fig. 3). In contrast, neuronal overexpression of NEP
significantly reduced TS-positive deposits of intraneuronally
expressed A42 in the fly brain (Fig. 4). These results suggest
that residual A42 in fly brains with NEP overexpression may
not form TS-positive aggregates. What is the nature of this
NEP-insensitive fraction of A42? In this fly model, all A42 is
generated in the ER and distributed into the secretory pathway
(23). Some A42 may be transported into cellular compart-
ments where NEP cannot act because of the unfavorable pH
environment. In addition, A42 peptides with particular mis-
folded structures may be resistant to NEP degradation. In fact,
pathogenic mutations in A make it resistant to proteolytic
degradation by NEP in vitro (63). Interestingly, our recent
results suggest that the particular aggregation propensities of
A42 influence the cellular localization of A42 in this fly
model (23), suggesting that the misfolding properties of A42
may affect its sensitivity toNEP by altering the cellular localiza-
tion. We hypothesize that this NEP-insensitive population of
A42may contribute to the premature death phenotype, which
was not rescued by NEP overexpression in our fly models. Sev-
eral A-degrading enzymes are likely to contribute to A clear-
ance in the brain by complementing each other in a subcellular,
cell type, and/or brain region-specific manner (32). Insulin-de-
grading enzyme and ECE1 have been shown to degrade intra-
cellular A42 in cultured cells (64, 65), suggesting that activa-
tion of these A-degrading enzymes together with NEP may
additively suppress intraneuronal A42-induced toxicity. Fur-
ther analysis, including the effect of other A-degrading
enzymes, will be required to address the nature of the NEP-
insensitive A42 fraction in our fly models.
NEP is involved in the metabolism of a number of regulatory
peptides in the mammalian nervous, cardiovascular, and
immune systems, and up- or down-regulation of NEP can lead
to a range of pathological conditions. For example, down-reg-
ulation of NEP has been detected in a number of distinct can-
cers (66), and up-regulation has been detected in gliomas (67).
Thus, although activation of NEP could be a potential disease-
modifying therapy for AD (68), the potential side effects of
chronic overexpression of NEP in the brain need to be carefully
evaluated.
We demonstrated here that transgenic overexpression of
human NEP in neurons shortened the life span of flies and
caused age-dependent axon degeneration in the brain. More-
over, we found that NEP overexpression in neurons decreased
CREB-mediated transcription in the fly (Fig. 9), and reducing
CREB activity in neurons was sufficient to cause premature
death (Fig. 10). These data suggest that a reduction in CREB-
mediated transcription underlies premature death induced by
NEP overexpression. However, it is possible that premature
death and neurodegeneration induced by NEP expression is
because of a consequence ofmisexpression in brain regions that
do not usually express NEP, and enhancement of endogenous
NEP may not cause these effects.
Contrary to the detrimental effects of neuronal NEP expres-
sion in flies, it has been shown that transgenic mice expressing
NEP under the control of the neuron-specific CaM kinase II
promoter are healthy for up to 14 months without obvious
brain pathology (13). This may be one of the reasons why pre-
mature death inA42 flies was not rescued byNEP overexpres-
sion, although it is reported that NEP expression decreased
premature death in humanAPP transgenicmice (13).What is a
possible explanation for this discrepancy? In flies, dCREB2, a fly
homologue of mammalian CREB and cAMP-response element
modulator, plays a central role inCREB-mediated transcription
(34), and NEP-sensitive peptides play a dominant role in
homeostatic CREB activation (Fig. 9). In contrast, mice have
several CREB family members, including cAMP-response ele-
ment modulator with redundant functions, and signaling
mechanisms other than theNEP-sensitive pathway(s)may exist
to activate CREB-mediated transcription. Because CREB func-
tion is also known to be vital in mice (69), the lack of a severe
detrimental effect inNEP transgenicmicemay be due to a com-
plex compensation mechanism for CREB-mediated transcrip-
tion in mammalian brains. It would be important to examine
whether CREB-mediated transcription is altered in NEP trans-
genic mice.
NEP expression and activity are complexly regulated by
many factors that have been implicated in AD, including soma-
tostatin, estrogen, exercise, environmental enrichment, oxida-
tive stress, hypoxic and ischemic conditions, and aging (70).
Aging is the most significant risk factor for the development of
LOAD, and down-regulation of NEP and other A-degrading
enzymes in human and rodent brains have been hypothesized
to be involved in the increased risk for LOAD (68). In the Dro-
sophila genome, five NEP family genes (NEP1–5) have been
identified. Overexpression of Drosophila NEP2 (dNEP2), a fly
homologue of human NEP2, has been show to ameliorate
A42-induced retinal degeneration (71), although unlike
human NEP, NEP2 is a secreted protein (72). By quantitative
reverse transcription-PCR analysis, we found that the mRNA
levels of all fly NEPs, with the exception of NEP2, decreased
with age in the fly brain (Fig. 11). Of particular interest, this
trend is prominent for NEP1 and NEP3, whose mammalian
homologues are NEP and ECE1, respectively.
In summary, we have demonstrated the protective and det-
rimental aspects of chronically high NEP activity in the fly
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brain. Moreover, we observed age-dependent reduction in the
mRNA levels and activity of NEP inDrosophila brains. Elucida-
tion of the physiologicalmechanism(s) underlying age-depend-
ent down-regulation ofNEP in flies, which is a powerful genetic
model system, will facilitate our understanding of brain aging
and may lead to the discovery of novel therapeutics in AD.
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